Description:

Size: 100ul

Catalog no.: bs-9843R-A594

Price: 380 EUR

Product details

Gene ID Number

3053

Target Antigen

HCF2

Modification Site

None

Tested applications

IF(IHC-P)

French translation

anticorps

Modification

Unmodified

Clonality

Polyclonal

Excitation emission

590nm/617nm

Concentration

1ug per 1ul

Crossreactivity

Human, Mouse, Rat

Conjugated with

ALEXA FLUOR® 594

Conjugated

Alexa conjugate 1

Recommended dilutions

IF(IHC-P)(1:50-200)

Clone

Polyclonal antibody

Purification

Purified by Protein A.

Category

Conjugated Primary Antibodies

Also known as

Anti-HCF2 PAb ALEXA FLUOR 594

Conjugation

Alexa Fluor,ALEXA FLUOR® 594

Host Organism

Rabbit (Oryctolagus cuniculus)

Specificity

This is a highly specific antibody against HCF2.

Long name

HCF2 Polyclonal Antibody, ALEXA FLUOR 594 Conjugated

Synonyms

HC II; HCF2; HLS2; Leuserpin 2; LS2; Protease inhibitor leuserpin 2; SERPIND1; HEP2_HUMAN.

Cross-reactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Source

This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human HCF2/Heparin Cofactor II

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Properties

For facs or microscopy Alexa 1 conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Background of the antigen

The herpes simplex virus (HSV) infection is initiated by VP16, a viral transcription factor that activates the viral immediate-early (IE) genes.The anticoagulant action of heparin is dependent on plasma components termed heparin cofactors. The first of these to be well characterized was antithrombin III. Heparin Cofactor II is antigenically distinct from AT III. Heparin Cofactor II is normal in patients with AT III deficiency and is low in patients with disseminated intravascular coagulation. It is expressed predominantly in liver. Its function is: thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, Heparin Cofactor II becomes the predominant thrombin inhibitor in place of antithrombin III (AT III). Also inhibits chymotrypsin, but in a glycosaminoglycan independent manner and peptides at the N terminal of Heparin Cofactor II have chemotactic activity for both monocytes and neutrophils. The N terminal acidic repeat region mediates, in part, the glycosaminoglycan accelerated thrombin inhibition. Defects in SERPIND1 are the cause of Heparin Cofactor II deficiency. Heparin Cofactor II deficiency is an important risk factor for hereditary thrombophilia, a multifactorial trait characterized by recurrent thrombosis and abnormal platelet aggregation in response to various agents. Heparin Cofactor II deficiency is inherited as an autosomal dominant disorder, in which affected individuals are prone to develop serious spontaneous thrombosis.